Literature DB >> 3524431

Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo.

R J Boon, A S Beale, R Sutherland.   

Abstract

The comparative efficacies of ticarcillin and ticarcillin plus clavulanic acid have been determined in the mouse against experimental infections caused by ticarcillin-resistant bacteria. The infections studied comprised an intraperitoneal infection, local tissue infections, pyelonephritis, and pneumonia. Both ticarcillin and clavulanic acid penetrated readily to the sites of infection studied and at the doses employed were present at concentrations of the same order as those obtained in humans after the administration of ticarcillin-clavulanic acid formulations (Timentin; Beecham). At these concentrations, the ticarcillin-clavulanic acid combination caused significant bactericidal effects at the sites of infection against the ticarcillin-resistant strains of Bacteroides fragilis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus investigated. The efficacy of ticarcillin plus clavulanic acid against the infections resistant to therapy with ticarcillin demonstrated the beta-lactamase-inhibitory activity of clavulanic acid in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3524431      PMCID: PMC284163          DOI: 10.1128/AAC.29.5.838

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics.

Authors:  L Dumon; P Adriaens; J Anné; H Eyssen
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

Review 4.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

5.  Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli.

Authors:  J W Paisley; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

6.  Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid.

Authors:  S Bennett; R Wise; D Weston; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

7.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

8.  The penetration of amoxycillin/clavulanic acid into peritoneal fluid.

Authors:  R Wise; I A Donovan; J Drumm; J M Andrews; P Stephenson
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

9.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

10.  Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infections.

Authors:  R J Boon; A S Beale; K R Comber; C V Pierce; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

View more
  5 in total

1.  Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.

Authors:  A S Beale; J Gisby
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

2.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats.

Authors:  E J Catherall; V Gillon; S Hurn; R Irwin; L Mizen
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin.

Authors:  D Adam; H D Heilmann; K Weismeier
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Authors:  J L Fournier; F Ramisse; A C Jacolot; M Szatanik; O J Petitjean; J M Alonso; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.